Related Experiment Video
Updated: Jun 19, 2026

09:20
An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function
Published on: May 4, 2021
Adiponectin directly improves endothelial dysfunction in obese rats through the AMPK-eNOS Pathway
1Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu City, Sichuan Province, China.
International Journal of Obesity (2005)
|October 14, 2009
Summary
Adiponectin improves endothelial dysfunction in obese rats by increasing nitric oxide production. This study reveals adiponectin
Area of Science:
- Cardiovascular Research
- Endocrinology
- Molecular Biology
Background:
- Hypoadiponectinemia is linked to endothelial dysfunction and cardiovascular disease risk.
- Obesity induced by high-fat diets exacerbates endothelial dysfunction.
Purpose of the Study:
- To investigate adiponectin's effect on endothelial dysfunction in high-fat diet-induced obese rats.
- To elucidate the underlying mechanisms of adiponectin's action on the aorta.
Main Methods:
- Male Sprague-Dawley rats were fed high-fat or regular diets for 6 weeks.
- Isolated rat aortic segments and human aortic endothelial cells were treated with globular adiponectin (gAD).
- Endothelial function, nitric oxide (NO) production, and protein phosphorylation (eNOS, AMPK, Akt) were assessed.
Main Results:
- High-fat diet induced severe endothelial dysfunction in rat aortas.
- gAD partially improved endothelium-dependent relaxation and increased NO production.
- gAD enhanced endothelial nitric oxide synthase (eNOS) activity via AMPK phosphorylation in endothelial cells.
Conclusions:
- Adiponectin reverses diet-induced endothelial dysfunction.
- Adiponectin increases NO production by phosphorylating eNOS and reduces NO inactivation.
- This suggests a novel therapeutic strategy for preventing vascular injury in obesity.
Related Concept Videos
cAMP-dependent Protein Kinase Pathways
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
